Catawba Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Catawba Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.12M	Buy	11,760 +140	+1%	+$12.9K	0.26%	85
2018 Q1	$1.02M	Sell	11,620 -2,975	-20%	-$272K	0.24%	88
2017 Q4	$1.24M	Sell	14,595 -35	-0.2%	-$2.93K	0.28%	81
2017 Q3	$1.27M	Buy	14,630 +1,605	+12%	+$129K	0.29%	83
2017 Q2	$1M	Buy	13,025 +4,795	+58%	+$340K	0.23%	94
2017 Q1	$571K	Buy	+8,230	New	+$553K	0.12%	150

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Catawba Capital Management's XBI Position: Q2 2018 in Review

Catawba Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.2% in Q2 2018, buying an estimated $12.9K and bringing the position to 11,760 shares worth $1.12M. The position accounts for 0.26% of the portfolio, ranked #85.

Catawba Capital Management first reported a position in XBI in Q1 2017 and has held it in 6 quarters since. The position peaked at $1.27M in Q3 2017. 430 funds tracked by Wall St. Rank hold XBI as of Q2 2018.

Catawba Capital Management held 11,760 shares of State Street SPDR S&P Biotech ETF worth $1.12M as of Q2 2018.
Catawba Capital Management bought 140 State Street SPDR S&P Biotech ETF shares in Q2 2018, an estimated $12.9K.
State Street SPDR S&P Biotech ETF made up 0.26% of Catawba Capital Management's portfolio in Q2 2018, its #85 holding.
Catawba Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 6 quarters since.
Catawba Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.27M in Q3 2017.
430 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.